BCR and chronic myelogenous leukemia, BCR-ABL1 positive: A phase 2 trial investigated the effect of ponatinib on heavily pretreated CML patients who had either unacceptable side effects from dasatinib or nilotinib or who had the BCR::ABL1 T315I mutation.